Pharmacist‐Provided Anticoagulation Management in United States Hospitals: Death Rates, Length of Stay, Medicare Charges, Bleeding Complications, and Transfusions
Authors:
- 1 August 2004
- journal article
- review article
- Published by Wiley in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Vol. 24 (8) , 953-963
Abstract
We explored the associations between pharmacist‐provided anticoagulation management in hospitalized Medicare patients and several major heath care outcomes: death rate, length of stay, Medicare charges, bleeding complications, and transfusions. Using the 1995 National Clinical Pharmacy Services database and the 1995 Medicare database for hospitals, data were retrieved for 717,396 Medicare patients treated in 955 hospitals for conditions requiring anticoagulant therapy. In hospitals without pharmacist‐provided heparin management, death rates were 11.41% higher (χ2 (1) = 122.84, pU test = 40039529342, pU = 41004749266, p2 (1) = 10.996, p=0.0009) and the transfusion rate for bleeding complications was 5.47% higher (χ2 (1) = 11.24, p=0.0008) than in hospitals with pharmacist‐provided heparin management. In hospitals without pharmacist‐provided warfarin management, death rates were 6.20% higher (χ2 (1) = 19.20, pU = 25730993838, pU = 259955112970, p2 (1) = 49.259, p2 (1) = 78.68, p<0.0001). Study hospitals without pharmacist‐provided heparin management had 4664 more deaths, 494,855 more patient‐days, 145 more patients with bleeding complications, and $651,274,844 more in patient charges; 9784 more units of whole blood were used in patients requiring transfusions for bleeding complications. Hospitals without pharmacist‐provided warfarin management had 2786 more deaths, 316,589 more patient‐days, 429 more patients with bleeding complications, and $234,275,490 more in patient charges; 8991 more units of whole blood were used in patients requiring transfusions for bleeding complications. The implications of these findings are significant for the health care system, especially considering that the study population represents 28.25% of hospitalized Medicare patients who should receive anticoagulants, and that total Medicare admissions represent 35.02% of total admissions to United States hospitals.Keywords
This publication has 31 references indexed in Scilit:
- Collaborative Drug Therapy Management by Pharmacists—2003Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2003
- The Quality of Health Care Delivered to Adults in the United StatesNew England Journal of Medicine, 2003
- Evidence of the Economic Benefit of Clinical Pharmacy Services: 1996–2000Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2003
- Reduction in Heart Failure Events by the Addition of a Clinical Pharmacist to the Heart Failure Management TeamArchives of internal medicine (1960), 1999
- Comparison of an Anticoagulation Clinic With Usual Medical CareArchives of internal medicine (1960), 1998
- Hospital Characteristics and Mortality RatesNew England Journal of Medicine, 1989
- Adjusted hospital death rates: a potential screen for quality of medical care.American Journal of Public Health, 1987
- Sustained Improvement in Drug Documentation, Compliance, and Disease ControlArchives of internal medicine (1960), 1984
- Improving Drug-Therapy Decisions through Educational OutreachNew England Journal of Medicine, 1983
- Role of the Clinical Pharmacist in Improving Drug TherapyArchives of internal medicine (1960), 1981